0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Debora Fumagalli, MD, PhD; David Venet, PhD; Michail Ignatiadis, MD, PhD; et al.
JAMA Oncol. Published online September 29, 2016. doi:10.1001/jamaoncol.2016.3824
Includes: Supplemental Content

JAMA Oncology | 
Viewpoint |  ONLINE FIRST
Ines Vaz-Luis, MD, MSc; Harold J. Burstein, MD, PhD
JAMA Oncol. Published online September 15, 2016. doi:10.1001/jamaoncol.2016.3631

JAMA Oncology | 
Editorial |  ONLINE FIRST
Marissa Howard-McNatt, MD
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3136

JAMA Oncology | 
Editorial |  ONLINE FIRST
Laurie W. Cuttino, MD; Charlotte Dai Kubicky, MD, PhD
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3137

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Tehillah S. Menes, MD; Karla Kerlikowske, MD; Jane Lange, PhD; et al.
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3022
Includes: Supplemental Content

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Conny Vrieling, MD, PhD; Erik van Werkhoven, MSc; Philippe Maingon, MD, PhD; et al.
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3031
Includes: Supplemental Content

JAMA | 
Lab Reports | 
Tracy Hampton, PhD
JAMA. 2016;316(9):917. doi:10.1001/jama.2016.12068.

JAMA Oncology | 
Invited Commentary | 
Robert Zachariae, DMSc
JAMA Oncol. 2016;2(9):1177-1178. doi:10.1001/jamaoncol.2016.0713.

JAMA Oncology | 
Original Investigation | 
Heather Greenlee, ND, PhD; Alfred I. Neugut, MD, PhD; Laura Falci, MPH; et al.
JAMA Oncol. 2016;2(9):1170-1176. doi:10.1001/jamaoncol.2016.0685.
Includes: Supplemental Content

JAMA Oncology | 
Viewpoint | 
Alison M. Brann, BS; Melody A. Cobleigh, MD; Tochi M. Okwuosa, DO
JAMA Oncol. 2016;2(9):1123-1124. doi:10.1001/jamaoncol.2016.1288.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Original Investigation  | 
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, MD, PhD; David Venet, PhD; Michail Ignatiadis, MD, PhD; et al.
JAMA Oncology
Viewpoint  | 
Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer
Ines Vaz-Luis, MD, MSc; Harold J. Burstein, MD, PhD
JAMA Oncology
Editorial  | 
Atypical Ductal Hyperplasia What Is the Current Risk for Developing Breast Cancer?
Marissa Howard-McNatt, MD
JAMA Oncology
Editorial  | 
Who Benefits From a Tumor Bed Boost After Whole-Breast Radiotherapy?
Laurie W. Cuttino, MD; Charlotte Dai Kubicky, MD, PhD